Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday&#

Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader

RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others g

Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price tar

Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing com

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesda

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in

Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Wei

NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds

Dimensional Fund Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN)

Assenagon Asset Management S.A. decreased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 28

Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free R

Myriad Genetics (MYGN) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Au

Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughl

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered L

Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Str

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating pot

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Ge

Myriad Genetics Investigation Notice: Levi and Korsinsky Notifies Investors of Pending Investigation

On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just t

Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the

Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr

Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to

Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the

Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight

Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analys

Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price tar

Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight